Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities in acute myeloid leukemia (AML). We determined the NPM1 mutation status in a clinically and molecularly well-characterized patient cohort of 275 patients with newly diagnosed AML by denaturing high performance liquid chromatography (dHPLC). We show that NPM1 mutations are significantly underrepresented in patients younger than 35yr. prognostic value with regard to overall-, event free-and disease free survival.
ABSTRACT
Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities in acute myeloid leukemia (AML). We determined the NPM1 mutation status in a clinically and molecularly well-characterized patient cohort of 275 patients with newly diagnosed AML by denaturing high performance liquid chromatography (dHPLC). We show that NPM1 mutations are significantly underrepresented in patients younger than 35yr. NPM1 mutations positively correlate with AML with high white blood cell counts, normal karyotypes and FLT3 internal tandem duplication (ITD) mutations. NPM1 mutations associate inversely with the occurrence of CEBPA-and N-RAS mutations. With respect to gene expression profiling, we show that AML cases with an NPM1 mutation cluster in specific subtypes of AML with previously established gene expression signatures, are highly associated with a homeobox gene-specific expression signature and can be predicted with high accuracy. We demonstrate that patients with intermediate cytogenetic risk AML without FLT3 ITD mutations but with NPM1 mutations have a significantly better OS and EFS than those without NPM1 mutations. Finally, in multivariable analysis NPM1 mutations express independent favorable prognostic value with regard to overall-, event free-and disease free survival.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disease with diverse genetic abnormalities and variable responsiveness to therapy. Cytogenetic analyses and molecular analyses are currently used to risk-stratify AML. For instance, the translocations inv(16), t(8;21), and t(15;17) herald a favorable prognosis, whereas certain other cytogenetic aberrations indicate leukemia with intermediate or high risk of relapse [1] [2] [3] [4] [5] . Nevertheless, the classification of AML on the basis of karyotyping is still far from satisfactory. In recent years extended molecular analyses have yielded novel molecular markers important for proper diagnostics of AML. The ITD in the fms-like tyrosine kinase-3 gene (FLT3) 6, 7 , partial tandem duplication (PTD) Mutations of NPM1 were found to be mutually exclusive with certain common recurrent chromosomal aberrations, and are predominantly seen in AML with normal karyotypes and FLT3 ITD mutations.
NPM1 is predominantly localized in the nucleolus and is thought to function as a molecular chaperone of proteins, facilitating the transport of ribosomal proteins through the nuclear membrane [14] [15] [16] . Disruption of NPM1, either by chromosomal translocation or by mutation, results in the cytoplasmic dislocation of NPM1. The high frequency of NPM1 mutations in AML with normal karyotypes and the observation that cytoplasmic NPM1 cannot exert
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From its normal functions as binding partner and transporter protein lead to the notion that NPM1 mutation may be an early event in leukemogenesis.
An important role for NPM1 in leukemias and lymphomas has been proposed previously. NPM1 has been found to be part of several fusion proteins, which are formed as a result of chromosomal translocation and in which only the NPM1 N-terminal region is conserved. A t(2;5)(p23;q35) chromosomal translocation occurs in approximately 8% of non-Hodgkin lymphomas in children and young adults and results in the chimeric fusion of NPM1 to ALK 17 . In rare cases of acute promyelocytic leukemia (APL), characterized by chromosomal translocations that disrupt the gene encoding the retinoic acid receptor (RARA), fusion of NPM1 to RARA was shown 18 . A t(3;5)(q25. 
PCR, WAVE and sequence analyses
RNA isolation and cDNA synthesis were performed as described 21, 28 . cDNA prepared from 50ng of RNA was used for all PCR amplifications. NPM1 mutations in exon 12 were determined by cDNA amplification using the primers NPM1-FOR 5'-CTTCCGGATGACTGACCAAGAG-3' and primer PCR products were purified using the Multiscreen-PCR 96-well system (Millipore, Bedford, MA) followed by direct sequencing with NPM1-REV using an ABI-PRISM3100 genetic analyzer (Applied Biosytems, Foster City, CA).
Sequence analyses for mutations in FLT3 (ITD and tyrosine kinase domain mutation (TKD)), N-RAS, K-RAS and CEBPA performed as described previously.
12,30,31 .
Gene expression profiling and unsupervised cluster analyses
285 AML cases were analyzed using Affymetrix HGU133A GeneChips 21 .
Unsupervised cluster analysis on the basis of the gene expression profiles of the 285 cases of AML was performed using the Correlation Visualization tool Figure 1 ). MADEx is a database system that stores, mines and visualizes microarray data in a secure and scalable manner.
Significance Analysis of Microarrays (SAM)
All supervised analyses were performed using Significance Analysis of Microarrays (SAM) (version 1.21)
32
. A threshold was set for a minimum change in expression of at least 1.5-fold. A false discovery rate of 0.01 was used to select the differentially expressed genes. (Table 1) .
NPM1 mutations in relation to clinical and molecular features in AML
The NPM1 mutation frequencies of the 275 cases of primary AML with regard to clinical parameters, morphology, cytogenetics and molecular characteristics are shown in Table 2 . NPM1 mutations are significantly less frequently present in patients of younger age (<35 yr, p<0.001). The mean age of patients with AML and NPM1 mutations is 47.3 (±10.7), whereas the mean age of patients with AML and wild-type NPM1 is 39,7 (±13. Table 1 ).
The identity of the Top-50 genes, in some cases represented by multiple probe sets, are depicted in Table 3 .
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From A dominant homeobox (HOX) gene-specific signature is strongly associated with AML carrying an NPM1 mutation. Moreover, the expression of members of the HOXA-and HOXB-gene families, but also the HOX gene-related TALE genes, PBX3 and MEIS1 are increased. In contrast, the CD34 gene is the strongest significantly down regulated gene with regard to NPM1 mutation in the AML patient cohort.
NPM1 mutant cases are predicted with high accuracy based on their gene expression signature NPM1 mutation prediction analyses were performed using the PAM algorithm 33 . All 275 primary AML samples were randomly assigned to a training set, consisting of 122 samples without NPM1 mutations and 62 samples with NPM1 mutations, and a validation series, consisting of 58 samples lacking the NPM1 mutation and 33 samples with mutations in NPM1. Cross validation to predict the mutation status of NPM1 on the training set resulted in 100% correct predictions on presence of mutation (sensitivity) and 80.3% correct predictions on absence of mutation (specificity) ( Table 4) . Prediction of an independent validation set also resulted in 100% correct prediction of presence of mutation and 82.7% correct prediction on absence of mutation.
The positive predictive value in this cohort is 72% in the training set and 74% overall. As expected, the genes included in the PAM gene signature were among the most significant differentially expressed genes as determined by SAM, thereby validating both algorithms. Of note, NPM1 mRNA expression did not correlate with mutation status (Figure 2 ). The NPM1 mutant AML cases have a distinct signature with regard to the 18 selected genes ( Figure   For 
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2) and are therefore predicted with high accuracy (Table 4 ). However, these 18 genes seem to be expressed at comparable levels in a subset of AML cases with wild type NPM1 (Figure 2 ).
NPM1 mutation is an independent favorable prognostic marker
To investigate the prognostic value of NPM1 mutation 252 AML patients with long term follow up following therapy completion were included for survival analysis. The EFS, OS and probability of relapse at 60 months for the AML patients with or without NPM1 mutations were similar ( Figures 3A and 3B ).
Likewise, among the subgroup with cytogenetics of intermediate prognostic risk EFS, OS and probability of relapse at 60 months were not different either ( Figures 3C and 3D) , although there appears a trend for more favorable outcome for patients with AML with NPM1 mutations. Since NPM1 mutations are significantly associated with both normal karyotype and presence of a FLT3 ITD (Table 2) (Table 5 ). In univariable analyses NPM1 mutation showed no statistical significance with respect to the endpoints. However, in multivariable analyses mutated NPM1 was significantly associated with a much lower hazard ratio, However, the common underlying molecular abnormality for the other subtypes of AML was unknown. In the present study we show that two clusters consist entirely of AML cases with NPM1 mutations, i.e., clusters #6
and #11, whereas clusters #2, #3, #5 and #7 predominantly include patients with NPM1 mutations. Thus, we identify mutant NPM1 as a common molecular abnormality in these subtypes of AML. We detected the various mutation variants of NPM1 at similar frequencies as was described recently 13 , and also identified three novel mutant variants.
These novel variants carry, like the other NPM1 mutant variants in our study, an insertion of 4 bp, resulting in a protein with an altered C-terminus (Table 1) .
Falini and colleagues 13 suggested that the disruption of one of the two Cterminal tryptophan residues and the last five residues, i.e., VSLRK, are important for NPM1 mutant function. Our study suggests that the final 9
For By univariate analyses we show that there is a tendency that the presence of an NPM1 mutation, and concomitant low CD34 mRNA expression, is a favorable marker for clinical outcome (Figure 3 ). This is in agreement with (Figure 4 ). In addition, we note that in the multivariable analyses the effect of NPM1 mutations is more pronounced than is apparent in the univariable analyses. This is not only true for NPM1 mutations, but also for the independent prognostic effect of FLT3 ITD mutations, age and cytogenetic risk ( Table 5 ).
The data presented here demonstrate that the frequent C-terminal insertion mutations in NPM1 correlate with favorable outcome for patients with AML.
Since NPM1 mutations are predominantly found in patients with standard risk AML, determination of the NPM1 mutation status, in combination with other 
30.
Valk PJM, Bowen DT, Frew ME, Goodeve AC, Löwenberg B, Reilly JT. . The number of probe sets used in this prediction was 22, which represent 18 unique genes.
10-fold CV error: 10-fold cross validation prediction error on training set (n=184), Error validation set: prediction error on validation set (n=91). 10-Fold cross validation works as follows: the model is fitted on 90% of the samples and the class of the remaining 10% is predicted. This procedure is repeated 10 times, with each part playing the role of the test samples and the error of all 10 parts added together to compute the overall error. The error within the validation set reflects the number of samples wrongfully predicted in this set.
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